Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Multicenter, Observational Study to Evaluate Physical Activity, Bleeding Events, Quality of Daily Life, and Safety in Patients with Congenital Hemophilia A Without FVIII Inhibitors Under Emicizumab Prophylaxis

Next Previous
Search
Trial Profile

Prospective, Multicenter, Observational Study to Evaluate Physical Activity, Bleeding Events, Quality of Daily Life, and Safety in Patients with Congenital Hemophilia A Without FVIII Inhibitors Under Emicizumab Prophylaxis

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emicizumab (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TSUBASA
  • Sponsors Chugai Pharmaceutical

    • Most Recent Events

    • 01 Jan 2024 Results assessing the association of physical activity with bleeding and safety in PwHA starting emicizumab, were published in the International Journal of Hematology.
    • 06 Jul 2022 Status changed from recruiting to active, no longer recruiting.
    • 01 Jul 2020 Planned End Date changed from 18 Sep 2022 to 31 Oct 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top